Case number 1:22-cv-01061
Neurocrine Biosciences, Inc. v. Lupin Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 14, 2023 | 18 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb) (Entered: 11/14/2023) (0) |
| Nov 13, 2023 | 17 | SO ORDERED re (22 in 1:21-cv-01408-MN, 277 in 1:21-cv-01042-MN, 16 in 1:22-cv-00639-MN, 16 in 1:22-cv-01061-MN) Stipulated Dismissal. Signed by Judge Maryellen Noreika on 11/13/2023. (dlw) (Entered: 11/13/2023) (2) |
| Nov 10, 2023 | 16 | STIPULATION of Dismissal Without Prejudice (as to Lupin Limited, and Lupin Pharmaceuticals, Inc.) by Neurocrine Biosciences, Inc. (Mayo, Andrew) Modified on 11/13/2023 (dlw). (Entered: 11/10/2023) (2) |
| Nov 9, 2023 | 15 | SO ORDERED re (14 in 1:22-cv-00639-MN) (275 in 1:21-cv-01042-MN) (14 in 1:22-cv-01061-MN) (20 in 1:21-cv-01408-MN) Stipulation and Order Dismissing Without Prejudice Defendants Lupin, Inc. and Lupin Atlantis Holdings, S.A. and Amending Caption in the Action to Reflect Same. Party Lupin Atlantis Holdings S.A. and Lupin Inc. terminated. Attorney Jillian M. Schurr; James Michael Lennon and Jitendra M. Malik terminated as to these defendants. Signed by Judge Maryellen Noreika on 11/9/2023. (dlw) (Entered: 11/09/2023) (3) |
| Nov 8, 2023 | 14 | STIPULATION Dismissing Without Prejudice Defendants Lupin, Inc. and Lupin Atlantic Holdings, S.A. and Amending Caption to Reflect Same by Lupin Atlantis Holdings S.A., Lupin Inc., Lupin Limited, Lupin Pharmaceuticals, Inc. (Lennon, James) Modified on 11/9/2023 (dlw). (Entered: 11/08/2023) (3) |
| Nov 18, 2022 | 13 | SO ORDERED re (12 in 1:22-cv-00639-MN, 12 in 1:22-cv-01061-MN) Stipulation and Order Regarding Case Consolidation. Signed by Judge Maryellen Noreika on 11/18/2022. (dlw) (Entered: 11/18/2022) (3) |
| Nov 17, 2022 | 12 | STIPULATION Regarding Consolidation, Case Schedule, and Protective Order, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/17/2022) (3) |
| Nov 10, 2022 | 11 | STIPULATION Seeking to Extend the Deadline by Which the Parties in the Non-Consolidated Cases Must Inform the Court Whether they Agree to be Consolidated With, and Adopt the Schedule of the Lead Case, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/10/2022) (5) |
| Oct 19, 2022 | 10 | ORAL ORDER RESETTING Teleconference - IT IS HEREBY ORDERED that the 10/24/2022 teleconference is RESET for 11/3/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/19/2022. (dlw) (Entered: 10/19/2022) (0) |
| Oct 14, 2022 | 9 | NOTICE OF SERVICE of Neurocrine Biosciences, Inc.'s First Set of Requests to Defendants for the Production of Documents and Things (Nos. 1-41) filed by Neurocrine Biosciences, Inc..(Mayo, Andrew) (Entered: 10/14/2022) (4) |
| Oct 6, 2022 | 8 | ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 10/24/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/6/2022. (dlw) (Entered: 10/06/2022) (0) |
| Sep 30, 2022 | 7 | ANSWER to 6 Answer to Complaint, Counterclaim by Neurocrine Biosciences, Inc..(Balick, Steven) (Entered: 09/30/2022) (7) |
| Sep 9, 2022 | 6 | ANSWER to 1 Complaint, , COUNTERCLAIM against Neurocrine Biosciences, Inc. by Lupin Inc., Lupin Limited, Lupin Atlantis Holdings S.A., Lupin Pharmaceuticals, Inc..(Lennon, James) (Entered: 09/09/2022) (27) |
| Aug 11, 2022 | 1 | Complaint* (1) |
| Aug 11, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) (Entered: 08/12/2022) (3) |
| Aug 11, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/28/2022. Date of Expiration of Patent: 9/18/2038.Thirty Month Stay Deadline: 10/11/2024. (lam) (Entered: 08/12/2022) (2) |
| Aug 11, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,311,532. (lam) (Entered: 08/12/2022) (1) |
| Aug 11, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (lam) (Entered: 08/12/2022) (1) |
